Literature DB >> 2841690

Increased leukotriene B4 in bronchoalveolar lavage fluid and plasma of endotoxemic pigs.

N C Olson1, R T Dobrowsky, L N Fleisher.   

Abstract

We hypothesized that leukotriene B4 (LTB4) might be produced during endotoxin-induced acute respiratory failure (ARF) observed in young pigs. We used radioimmunoassay (RIA) and reverse phase-high performance liquid chromatography (RP-HPLC) to determine the presence of LTB4 in plasma and bronchoalveolar lavage fluid (BALF) of saline- and endotoxin-treated pigs. Endotoxin was infused at 5 micrograms/kg for 1 hour (hr) followed by 2 micrograms/kg/hr for an average of 3 hrs. Arterial plasma (collected at 0.5 hr intervals for 4 hrs) immunoreactive (i)-LTB4 was significantly increased from 2.5 to 4 hrs of endotoxemia with the peak value occurring at 3.5 hrs (i.e. 282% of baseline value). Analysis of plasma extracts using RP-HPLC revealed an ultraviolet (UV) absorbance peak (270 nm) that was coincident with authentic LTB4 standard. The levels of i-LTB4 were significantly increased in BALF recovered from endotoxemic pigs (337 +/- 71 vs 53 +/- 13 pg/ml for saline controls). Endotoxin also increased the postmortem wet/dry ratio of bloodless lung and BALF albumin concentration, indicating pulmonary edema and increased permeability of the alveolar-capillary membrane, respectively. We conclude that LTB4 is increased in plasma and BALF recovered from endotoxemic pigs and that this lipoxygenase metabolite could possibly be an important factor contributing to the pathophysiology of endotoxin-induced ARF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841690     DOI: 10.1016/0952-3278(88)90096-8

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  1 in total

1.  Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans.

Authors:  Andreas Barratt-Due; Ebbe Billmann Thorgersen; Julie Katrine Lindstad; Anne Pharo; Olga Lissina; John D Lambris; Miles A Nunn; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2011-09-30       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.